A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer.

Locally Advanced Gastric Cancer Clinical Trial

Official title:

A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02192983
• Other study ID #: zswy002
• Status: Completed
• Phase: N/A
• First received: July 15, 2014
• Last updated: November 30, 2015
• Start date: November 2008
• Est. completion date: May 2015

Study information

• Verified date: November 2015
• Source: Shanghai Zhongshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study is designed to assess what is the better neoadjuvant chemotherapy regimen for patients with initially unresectable locally advanced gastric cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 242
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• more than 2 regional bulky lymph nodes macroscopic tumor type is either the Borrmann type 4 or large type 3 tumor invades adjacent structures (T4b)

Exclusion Criteria:

• peritoneal metastasis confirmed by CT scan lung metastasis, liver metastasis, pleural effusion, and/or other distant metastasis

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Locally Advanced Gastric Cancer
• Stomach Neoplasms

Locations

Country	Name	City	State
China	Shanghai Zhongshan Ethics Committee	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Tianshu Liu

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate		6 months after diagnosis	No